How has proteomics informed transfusion biology so far?

Abstract 

Since the genomic era has not fully kept its promises, studies addressing the protein complement to the genome have been recently gaining momentum. Proteomics investigations could be potentially used from bench to bedside, in order to test the quality of collected blood components prior to or during storage. In parallel, proteomics could be used to verify the effects of the production and pathogen reduction processes of plasma derivatives and blood components on the protein fractions, or to reduce the effects of storage lesions. Another area of interest is represented by the discovery of peculiar biomarkers readily adoptable for targeted evaluation of blood-component integrity or functionality, as well as to assess the proliferative capacity of hematopoietic stem/progenitor cells. These accumulating basic research evidences will hopefully be accompanied by actual applications in routine clinical practice. Whether the costs of the needed facilities (instruments and trained personnel) will meet the current demand of the clinical market, proteomic-expert transfusionists will no longer only inform, but also perform a role in clinical routine.

Abbreviations: A1AT, α1-antitrypsin, FFP, fresh frozen plasma, HSC, hematopoietic stem cell, MB, methylene blue, PCC, prothrombin complex concentrate, PLT, platelets, RBC, red blood cells, TM, transfusion medicine

Keywords: Transfusion medicine, Proteomics, Plasma, Platelet, Red blood cell, Plasma derivative products